227 related articles for article (PubMed ID: 19652664)
1. Common polymorphisms in CYP2C9, subclinical atherosclerosis and risk of ischemic vascular disease in 52,000 individuals.
Kaur-Knudsen D; Bojesen SE; Nordestgaard BG
Pharmacogenomics J; 2009 Oct; 9(5):327-32. PubMed ID: 19652664
[TBL] [Abstract][Full Text] [Related]
2. Functional promoter variant in zinc finger protein 202 predicts severe atherosclerosis and ischemic heart disease.
Stene MC; Frikke-Schmidt R; Nordestgaard BG; Grande P; Schnohr P; Tybjaerg-Hansen A
J Am Coll Cardiol; 2008 Jul; 52(5):369-77. PubMed ID: 18652945
[TBL] [Abstract][Full Text] [Related]
3. Common variation in cytochrome P450 epoxygenase genes and the risk of incident nonfatal myocardial infarction and ischemic stroke.
Marciante KD; Totah RA; Heckbert SR; Smith NL; Lemaitre RN; Lumley T; Rice KM; Hindorff LA; Bis JC; Hartman B; Psaty BM
Pharmacogenet Genomics; 2008 Jun; 18(6):535-43. PubMed ID: 18496133
[TBL] [Abstract][Full Text] [Related]
4. Genetic susceptibility to nonsteroidal anti-inflammatory drug-related gastroduodenal bleeding: role of cytochrome P450 2C9 polymorphisms.
Pilotto A; Seripa D; Franceschi M; Scarcelli C; Colaizzo D; Grandone E; Niro V; Andriulli A; Leandro G; Di Mario F; Dallapiccola B
Gastroenterology; 2007 Aug; 133(2):465-71. PubMed ID: 17681167
[TBL] [Abstract][Full Text] [Related]
5. Promotor polymorphisms in leukotriene C4 synthase and risk of ischemic cerebrovascular disease.
Freiberg JJ; Tybjaerg-Hansen A; Sillesen H; Jensen GB; Nordestgaard BG
Arterioscler Thromb Vasc Biol; 2008 May; 28(5):990-6. PubMed ID: 18276912
[TBL] [Abstract][Full Text] [Related]
6. The risk of myocardial infarction in patients with reduced activity of cytochrome P450 2C9.
Visser LE; van Schaik RH; Jan Danser AH; Hofman A; Witteman JC; van Duijn CM; Uitterlinden AG; Pols HA; Stricker BH
Pharmacogenet Genomics; 2007 Jul; 17(7):473-9. PubMed ID: 17558303
[TBL] [Abstract][Full Text] [Related]
7. Estrogen receptor alpha polymorphism and risk of cardiovascular disease, cancer, and hip fracture: cross-sectional, cohort, and case-control studies and a meta-analysis.
Kjaergaard AD; Ellervik C; Tybjaerg-Hansen A; Axelsson CK; Grønholdt ML; Grande P; Jensen GB; Nordestgaard BG
Circulation; 2007 Feb; 115(7):861-71. PubMed ID: 17309937
[TBL] [Abstract][Full Text] [Related]
8. Effects of cytochrome P450 2C9 polymorphisms on phenprocoumon anticoagulation status.
Schalekamp T; Oosterhof M; van Meegen E; van Der Meer FJ; Conemans J; Hermans M; Meijerman I; de Boer A
Clin Pharmacol Ther; 2004 Nov; 76(5):409-17. PubMed ID: 15536456
[TBL] [Abstract][Full Text] [Related]
9. Genetically reduced antioxidative protection and increased ischemic heart disease risk: The Copenhagen City Heart Study.
Juul K; Tybjaerg-Hansen A; Marklund S; Heegaard NH; Steffensen R; Sillesen H; Jensen G; Nordestgaard BG
Circulation; 2004 Jan; 109(1):59-65. PubMed ID: 14662715
[TBL] [Abstract][Full Text] [Related]
10. The association of CYP2C9 gene polymorphisms with colorectal carcinoma in Han Chinese.
Liao LH; Zhang H; Lai MP; Lau KW; Lai AK; Zhang JH; Wang Q; Wei W; Chai JH; Lung ML; Tai SS; Wu M
Clin Chim Acta; 2007 May; 380(1-2):191-6. PubMed ID: 17368604
[TBL] [Abstract][Full Text] [Related]
11. Genetic variance in CYP2C8 and increased risk of myocardial infarction.
Rodenburg EM; Visser LE; Danser AH; Hofman A; van Noord C; Witteman JC; Uitterlinden AG; Stricker BH
Pharmacogenet Genomics; 2010 Jul; 20(7):426-34. PubMed ID: 20436375
[TBL] [Abstract][Full Text] [Related]
12. Short telomere length, myocardial infarction, ischemic heart disease, and early death.
Weischer M; Bojesen SE; Cawthon RM; Freiberg JJ; Tybjærg-Hansen A; Nordestgaard BG
Arterioscler Thromb Vasc Biol; 2012 Mar; 32(3):822-9. PubMed ID: 22199369
[TBL] [Abstract][Full Text] [Related]
13. Association of OAZ1 gene polymorphisms with subclinical and clinical vascular events.
Dumont J; Zureik M; Bauters C; Grupposo MC; Cottel D; Montaye M; Hamon M; Ducimetière P; Amouyel P; Brousseau T
Arterioscler Thromb Vasc Biol; 2007 Oct; 27(10):2120-6. PubMed ID: 17761941
[TBL] [Abstract][Full Text] [Related]
14. CYP2C9 genotype does not affect risk of tobacco-related cancer in the general population.
Kaur-Knudsen D; Nordestgaard BG; Bojesen SE
Cancer Epidemiol; 2010 Apr; 34(2):178-83. PubMed ID: 20117066
[TBL] [Abstract][Full Text] [Related]
15. C-reactive protein and risk of venous thromboembolism in the general population.
Zacho J; Tybjaerg-Hansen A; Nordestgaard BG
Arterioscler Thromb Vasc Biol; 2010 Aug; 30(8):1672-8. PubMed ID: 20466978
[TBL] [Abstract][Full Text] [Related]
16. Mitochondrial haplogroups: ischemic cardiovascular disease, other diseases, mortality, and longevity in the general population.
Benn M; Schwartz M; Nordestgaard BG; Tybjaerg-Hansen A
Circulation; 2008 May; 117(19):2492-501. PubMed ID: 18458168
[TBL] [Abstract][Full Text] [Related]
17. CYP1B1 genotype and risk of cardiovascular disease, pulmonary disease, and cancer in 50,000 individuals.
Kaur-Knudsen D; Nordestgaard BG; Tybjaerg-Hansen A; Bojesen SE
Pharmacogenet Genomics; 2009 Sep; 19(9):685-94. PubMed ID: 19730035
[TBL] [Abstract][Full Text] [Related]
18. Cytochrome P450 2C9 *2 and *3 polymorphisms and the dose and effect of sulfonylurea in type II diabetes mellitus.
Becker ML; Visser LE; Trienekens PH; Hofman A; van Schaik RH; Stricker BH
Clin Pharmacol Ther; 2008 Feb; 83(2):288-92. PubMed ID: 17597710
[TBL] [Abstract][Full Text] [Related]
19. Role of CYP2C9 and CYP2C19 polymorphisms in patients with atherosclerosis.
Ercan B; Ayaz L; Ciçek D; Tamer L
Cell Biochem Funct; 2008 Apr; 26(3):309-13. PubMed ID: 17868191
[TBL] [Abstract][Full Text] [Related]
20. Comparison of osteoprotegerin to traditional atherosclerotic risk factors and high-sensitivity C-reactive protein for diagnosis of atherosclerosis.
Mogelvang R; Pedersen SH; Flyvbjerg A; Bjerre M; Iversen AZ; Galatius S; Frystyk J; Jensen JS
Am J Cardiol; 2012 Feb; 109(4):515-20. PubMed ID: 22100028
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
